Patents by Inventor Yataro Daigo

Yataro Daigo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for Diagnosing Non-Small Cell Lung Cancer
    Publication number: 20080050378
    Abstract: Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
    Type: Application
    Filed: March 18, 2005
    Publication date: February 28, 2008
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Method for diagnosing non-small cell lung cancers
    Publication number: 20060024692
    Abstract: Disclosed are methods for detecting, diagnosing, treating and preventing non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes, whose expression is elevated in non-small cell lung cancer compared to non-cancerous tissues, are provided. Also disclosed are agents for treating and preventing non-small cell lung cancer as well as methods for identifying further compounds for treating and preventing non-small cell lung cancer.
    Type: Application
    Filed: March 24, 2005
    Publication date: February 2, 2006
    Applicants: Oncotherapy Science, Inc., The University of Tokyo
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Methods for damaging cells using effector functions of anti FAM3D antibodies
    Publication number: 20050214303
    Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-FAM3D antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-FAM3D antibody as an active ingredient for damaging FAM3D-expressing cells using antibody effector function. Since FAM3D is strongly expressed in lung cancer cells, the present invention is useful in lung cancer therapies.
    Type: Application
    Filed: March 24, 2004
    Publication date: September 29, 2005
    Applicants: Oncotherapy Science, Inc., Japan as Represented by the President of the University of Tokyo
    Inventors: Yusuke Nakamura, Yataro Daigo